We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Combines AI and Machine Learning to Detect Cancer Before It Becomes Visible or Symptomatic

By LabMedica International staff writers
Posted on 28 Dec 2021

A simple blood test combines Artificial Intelligence (AI) and Machine Learning (ML) advances to identify cancer before it is visible or symptomatic. More...

Flagship Pioneering (Cambridge, MA, USA) has launched Harbinger Health (Pune, MH, India), a bioplatform company pioneering the detection of early cancer with a simple blood test that combines AI and ML advances with its recent discoveries about the biology of early cancer. By using this Bio-AI approach to identify cancer before it is visible or symptomatic, Harbinger Health’s proprietary HarbingerHx platform has the potential to create an entirely new paradigm for cancer diagnosis, enabling early therapeutic interventions or prevention.

“Harbinger Health has the potential to revolutionize the way we detect, diagnose, and treat cancer, enabling interventions at a much earlier phase of the disease than is currently possible,” said Doug Cole, M.D., Co-Founder and Chairman, Harbinger Health and Managing Partner, Flagship Pioneering. “Unlike prior approaches that are purely statistical in nature, Harbinger’s approach is informed by its insights into specific biological events that take place early in the development of cancer. After three years of research and development within Flagship Labs, we have created a platform that harnesses these insights to enable high-resolution, blood-based assays. With Harbinger Health, we have the potential to intervene in the cancer continuum far earlier than ever before, thus increasing the opportunities to save more lives.”

“Harbinger Health is poised to redefine our approach to oncology, moving beyond cancer ‘staging,’ and toward early detection that enables the diagnosis and treatment of cancer and ultimately to effectively reduce morbidity and mortality associated with the disease,” said Stephen Hahn, M.D., CEO, Harbinger Health and CEO-Partner, Flagship Pioneering. “We are committed to developing our platform so there is access to early cancer detection for all individuals with a simple test. No one should be disadvantaged in the fight against cancer – it’s our goal to bring the power of this platform not only to those with access to the top cancer centers – but to everyone.”

Related Links:
Flagship Pioneering
Harbinger Health 


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Portable Electronic Pipette
Mini 96
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.